Increase of Non-Albicans Candida Species and Their Antifungal Susceptibility in Intensive Care Unit Patients (Mexico)

• Published in: Sn Comprehensive Clinical Medicine
• Main Authors: Calvillo-Medina, Rosa Paulina, Mejía-Romero, Rocio Alejandrina, Martínez-Neria, Magda, Olalde-Elias, Juan José, Domínguez-Márquez, Fernando
• Format: Web Resource
• Language: English
• Published: Durham Research Square 29.12.2021
• Subjects: Intensive care; Mexico
• DOI: 10.21203/rs.3.rs-891714/v1

In Mexico little is known about candidemia by non-albicans Candida species and regarding their antifungal susceptibility. Besides without antifungal tests, fluconazole is one of the most used in empirical therapy. In the present study, we included patients from intensive care unit of one hospital in Mexico (2019-2020) with compatible yeast infection clinical signs, symptoms. Based on cultivable isolates, yeasts were identified by automated instrument and by molecular method (PCR), and their susceptibilities to six antifungals were characterized at different concentrations. From 105 patients, yeast cultures were recovered and identified mainly non-albicans Candida species (57.2%); and the most prevalent was C. glabrata (41.9%). Followed by C. albicans, C. krusei, C. parapsilosis, C. tropicalis and Cryptococcus neoformans. The most common infection site was urine (56%), followed by the bronchial aspirate (30%). Mostly the isolated fungi were susceptible to 5-flucytosine (98%) and to amphotericin B. Mainly C. glabrata followed by C. krusei and C. tropicalis were resistant to different concentrations of itraconazole, miconazole, and fluconazole. The present investigation contributes to the knowledge of non-albicans Candida species infections in patients and, opens the possibility for a better understanding and management in antifungal empirical therapy.in Mexico.